Accurate diagnosis and staging are essential for the optimal management of cancer
patients. Positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose …

Bone is the most common site of metastasis for breast cancer. Bone metastasis significantly
affects both quality of life and survival of the breast cancer patient. Clinically, complications …

Breast cancer is a major disease with high morbidity and mortality in women worldwide.
Increased use of imaging biomarkers has been shown to add more information with clinical …

Quantitative analysis can potentially improve the accuracy and consistency of 18F-FDG PET,
particularly for the assessment of tumor response to treatment. Although not without …

In this analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in
breast cancer is reviewed. The analysis was limited to recent works by using state-of-the-art …

Multimodality imaging, as represented by its greatest exponent, PET/CT, has a firm place in
the evaluation of a patient presenting with cancer. With 18F-FDG, PET/CT is rapidly …

Response criteria represent the standard by which the efficacy of therapeutic agents is
determined in cancer trials. The most widely used criteria are based on the anatomic …

OBJECTIVE. FDG PET/CT affects the management of patients with breast cancer in multiple
settings, including initial staging, treatment response assessment, and evaluation of …

Simple Summary Despite the increased use of neoadjuvant chemotherapy in the early
setting of breast cancer, there is a clinical need for predictive markers of response in daily …

Currently, the clinical role of positron emission tomography (PET) and PET/computed
tomography (CT) in patients with breast cancer is to provide additional information in select …